Ticker brief
PCVX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
116
authors 14d
53
crowd 14d
+0.7σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-15 · now +0.45 (−1 bearish … +1 bullish)
Who spoke53
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -1.06 | 11 | +0.49 |
| @BiopharmIQ | B | · | 10 | +0.28 |
| @Pharmdca | C | -3.41 | 9 | +0.63 |
| @AlertsAndNews | C | -3.92 | 6 | +0.13 |
| @AjTrader7 | C | -1.83 | 4 | -0.35 |
| @cnfinancewatch | B | -1.23 | 4 | +0.30 |
| @OzmosiHealth | C | · | 3 | +0.25 |
| @DinoLeadingNews | C | +1.99 | 3 | +0.60 |
| @DekmarTrades | C | -0.59 | 3 | +0.33 |
| @Briefingcom | B | -2.26 | 3 | +0.60 |
| @OpenOutcrier | C | · | 3 | +0.05 |
| @akishore | C | -1.30 | 3 | +0.53 |
| @Tickeron | C | +1.53 | 3 | +0.10 |
| @BioStocks | C | -1.77 | 2 | +0.33 |
| @twinsight_x | C | +2.87 | 2 | +0.50 |
| @BPharmCatalyst | C | · | 2 | +0.15 |
| @OptionRunners | C | -0.44 | 2 | +0.78 |
| @UTEX_io | C | +0.04 | 2 | +0.48 |
| @bullishchart | C | -1.21 | 2 | +0.52 |
| @Brad_E_Schulz | C | · | 2 | +0.00 |
| @ClassicRoy | C | -1.10 | 2 | +0.17 |
| @zohmbastic | C | -2.94 | 2 | -0.02 |
| @BottomPhishing | B | -0.28 | 2 | +0.50 |
| @NirAoo7 | C | -1.64 | 2 | +0.23 |
| @Optimalinvestme | C | -2.28 | 1 | +0.45 |
Recent signals30of 116 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @Pharmdca | +0.45 | Watchlist identifies potential support and bounce setups; PCVX is called a buy opportunity. | · | tweet ↗ |
| 2026-10-12 | @semodough | +0.40 | Cantor established a formal $120 target, above its prior informal $97 valuation. | · | tweet ↗ |
| 2026-10-10 | @dangerousteee | +0.60 | Reports percentage performance in a market review for October 5–9. | · | tweet ↗ |
| 2026-10-10 | @BiopharmIQ | +0.20 | Ranks biotech names by hedge-fund mentions in the platform's Q3 dataset. | · | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | +0.50 | Summarizes large biotech moves tied to a buyout and trial outcomes, then flags upcoming studies. | · | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | +0.50 | Weekly biotech event roundup covering acquisition, clinical data, FDA status, licensing, and a trial miss. | · | tweet ↗ |
| 2026-10-09 | @NirAoo7 | +0.20 | Screens liquid Stage 2/2A stocks with DCR above 80% and gains exceeding 4%. | · | tweet ↗ |
| 2026-10-09 | @OptionsFlowBoss | +0.65 | Explicitly reports bullish PCVX positioning. | · | tweet ↗ |
| 2026-10-09 | @semodough | +0.55 | Expresses optimism about the large addressable markets for both companies. | · | tweet ↗ |
| 2026-10-09 | @Pharmdca | +0.80 | Added substantial PCVX and VKTX positions for a sentiment recovery. — Discloses meaningful additions and a bullish fundamental thesis for both biotechs. | · | tweet ↗ |
| 2026-10-09 | @sspencer_smb | +0.80 | Long PCVX after its range breakout, targeting the mid-$70s. — Explicitly discloses a long breakout trade with an upside objective. | · | tweet ↗ |
| 2026-10-09 | @NirAoo7 | +0.25 | Lists liquid relative-strength names from a chart screen. | · | tweet ↗ |
| 2026-10-08 | @cnfinancewatch | +0.70 | Buy MSFT, NVDA and PCVX at half-size subject to stated triggers and stops. — Names three buys with entries, invalidation levels, targets and half-position sizing. | · | tweet ↗ |
| 2026-10-07 | @OpenOutcrier | -0.20 | Recaps unusual put positioning across multiple securities. | · | tweet ↗ |
| 2026-10-07 | @BiopharmIQ | +0.00 | Summarizes midday biotech news and associated stock moves for a broad list. | · | tweet ↗ |
| 2026-10-07 | @Pharmdca | +0.35 | Argues biotech fear creates opportunity and VKTX is compelling ahead of a major readout. | · | tweet ↗ |
| 2026-10-07 | @Pharmdca | +0.80 | Buy PCVX for the long term after its post-data pullback. — Calls PCVX a long-term buying opportunity after strong Phase 3 results and de-risking. | · | tweet ↗ |
| 2026-10-07 | @Pharmdca | +0.85 | Accumulate PCVX selectively on pullbacks and remain patient. — Explicitly recommends accumulating PCVX after strong clinical data and a retracement. | · | tweet ↗ |
| 2026-10-07 | @investseekers | +0.30 | Reports an AI clinical-trial model's predictions, track record and potential sector implications. | · | tweet ↗ |
| 2026-10-06 | @AlertsAndNews | +0.10 | Author adds five names to tomorrow's watch list without stating entry intent. | · | tweet ↗ |
| 2026-10-06 | @Pharmdca | +0.35 | Argues biotech is showing classic late-stage capitulation and bottom-forming conditions. | · | tweet ↗ |
| 2026-10-06 | @TheNewMoney_app | -0.60 | Reports PCVX options volume up 802% versus average with 86% puts. | · | tweet ↗ |
| 2026-10-06 | @OzmosiHealth | +0.00 | Vaxcyte presented Phase 3 VAX-31 results on 2026-10-05. | · | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | -0.35 | Biotech mover list quantifies the largest negative opening reactions and their associated catalysts. | · | tweet ↗ |
| 2026-10-06 | @Pharmdca | +0.80 | Adding more PCVX at current prices for the unchanged long-term setup. — Explicitly adds PCVX and argues the long-term thesis remains intact after the data spike faded. | · | tweet ↗ |
| 2026-10-06 | @SayNoToTrading | -0.55 | Identifies medtech-AI and genomics names dominating the day's losers amid company-specific events. | · | tweet ↗ |
| 2026-10-06 | @cnfinancewatch | +0.50 | Compiles bullish analyst, institutional, options, clinical, and insider catalysts. | · | tweet ↗ |
| 2026-10-06 | @Pharmdca | +0.80 | Opening a long-term PCVX position around $65. — Explicitly opens a long-term PCVX position near $65 and argues the setup is de-risked. | · | tweet ↗ |
| 2026-10-06 | @Tickeron | -0.60 | Reports a $1B stock-and-convertible financing package that dilutes shareholders. | · | tweet ↗ |
| 2026-10-06 | @UTEX_io | +0.40 | Reports that VAX-31 met all primary immunogenicity endpoints in a pivotal trial. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.